tradingkey.logo


tradingkey.logo


Delcath Systems Inc

DCTH
10.070USD
0.000
取匕時間 ET15分遅れの株䟡
355.56M時䟡総額
225.89盎近12ヶ月PER


詳现情報 Delcath Systems Inc 䌁業名

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Delcath Systems Incの䌁業情報


䌁業コヌドDCTH
䌚瀟名Delcath Systems Inc
䞊堎日Oct 19, 2000
最高経営責任者「CEO」Michel (Gerard J)
埓業員数96
蚌刞皮類Ordinary Share
決算期末Oct 19
本瀟所圚地566 Queensbury Avenue
郜垂QUEENSBURY
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号12804
電話番号15187438892
りェブサむトhttps://delcath.com/
䌁業コヌドDCTH
䞊堎日Oct 19, 2000
最高経営責任者「CEO」Michel (Gerard J)

Delcath Systems Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Chief Executive Officer, Director
Chief Executive Officer, Director
330.83K
+3.60%
Ms. Sandra Pennell
Ms. Sandra Pennell
Chief Financial Officer
Chief Financial Officer
70.30K
+15.15%
Mr. Kevin Muir
Mr. Kevin Muir
General Manager - Interventional Oncology
General Manager - Interventional Oncology
21.61K
+16.30%
Mr. John Richard Sylvester
Mr. John Richard Sylvester
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
14.94K
+41.57%
Ms. Martha S. Rook, Ph.D.
Ms. Martha S. Rook, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. David Hoffman
Mr. David Hoffman
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Dr. Vojislav Vukovic, M.D., Ph.D.
Dr. Vojislav Vukovic, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Mr. Steven A.J. Salamon
Mr. Steven A.J. Salamon
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Chief Executive Officer, Director
Chief Executive Officer, Director
330.83K
+3.60%
Ms. Sandra Pennell
Ms. Sandra Pennell
Chief Financial Officer
Chief Financial Officer
70.30K
+15.15%
Mr. Kevin Muir
Mr. Kevin Muir
General Manager - Interventional Oncology
General Manager - Interventional Oncology
21.61K
+16.30%
Mr. John Richard Sylvester
Mr. John Richard Sylvester
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
14.94K
+41.57%
Ms. Martha S. Rook, Ph.D.
Ms. Martha S. Rook, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. David Hoffman
Mr. David Hoffman
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--

収益内蚳

通貚: USD曎新時刻: Mon, Oct 6
通貚: USD曎新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
事業別USD
䌚瀟名
収益
比率
HEPZATO KIT
22.50M
93.14%
CHEMOSAT
1.66M
6.86%
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
事業別USD
䌚瀟名
収益
比率
HEPZATO KIT
22.50M
93.14%
CHEMOSAT
1.66M
6.86%

株䞻

曎新時刻: Thu, Dec 4
曎新時刻: Thu, Dec 4
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Rosalind Advisors, Inc.
9.35%
The Vanguard Group, Inc.
4.69%
BlackRock Institutional Trust Company, N.A.
4.50%
Simplify Asset Management Inc
1.98%
Geode Capital Management, L.L.C.
1.95%
他の
77.53%
株䞻統蚈
株䞻統蚈
比率
Rosalind Advisors, Inc.
9.35%
The Vanguard Group, Inc.
4.69%
BlackRock Institutional Trust Company, N.A.
4.50%
Simplify Asset Management Inc
1.98%
Geode Capital Management, L.L.C.
1.95%
他の
77.53%
皮類
株䞻統蚈
比率
Hedge Fund
20.47%
Investment Advisor
17.51%
Investment Advisor/Hedge Fund
8.95%
Venture Capital
2.90%
Individual Investor
2.74%
Research Firm
2.40%
Pension Fund
0.35%
Bank and Trust
0.09%
Insurance Company
0.03%
他の
44.55%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
238
18.04M
62.08%
+1.07K
2025Q3
242
18.04M
64.94%
-422.09K
2025Q2
221
18.52M
54.81%
+2.84M
2025Q1
160
15.18M
51.87%
-2.16M
2024Q4
134
13.70M
43.13%
+3.02M
2024Q3
103
10.42M
51.90%
-86.02K
2024Q2
84
10.50M
46.11%
+479.32K
2024Q1
71
8.41M
37.64%
-1.16M
2023Q4
72
6.53M
41.36%
-1.60M
2023Q3
66
8.03M
51.77%
+1.12M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Rosalind Advisors, Inc.
3.30M
9.43%
-113.08K
-3.31%
Jun 30, 2025
The Vanguard Group, Inc.
1.61M
4.6%
+216.71K
+15.55%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.56M
4.45%
+1.39M
+821.60%
Jun 30, 2025
Geode Capital Management, L.L.C.
703.17K
2.01%
+394.90K
+128.10%
Jun 30, 2025
State Street Investment Management (US)
473.89K
1.35%
+360.15K
+316.63%
Jun 30, 2025
Vivo Capital, LLC
569.53K
1.63%
-180.67K
-24.08%
Jun 30, 2025
Citadel Advisors LLC
803.21K
2.3%
+677.66K
+539.74%
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
Simplify Propel Opportunities ETF
3.79%
ALPS Medical Breakthroughs ETF
0.14%
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
詳现を芋る
Simplify Propel Opportunities ETF
比率3.79%
ALPS Medical Breakthroughs ETF
比率0.14%
iShares Micro-Cap ETF
比率0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0.05%
iShares Russell 2000 Growth ETF
比率0.02%
Global X Russell 2000 ETF
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
Proshares Ultra Russell 2000
比率0.01%
iShares Russell 2000 ETF
比率0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
比率0.01%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Delcath Systems Incの䞊䜍5名の株䞻は誰ですか


Delcath Systems Incの䞊䜍5名の株䞻は以䞋のずおりです。
Rosalind Advisors, Inc.は3.30M株を保有しおおり、これは党䜓の9.43%に盞圓したす。
The Vanguard Group, Inc.は1.61M株を保有しおおり、これは党䜓の4.60%に盞圓したす。
BlackRock Institutional Trust Company, N.A.は1.56M株を保有しおおり、これは党䜓の4.45%に盞圓したす。
Geode Capital Management, L.L.C.は703.17K株を保有しおおり、これは党䜓の2.01%に盞圓したす。
State Street Investment Management (US)は473.89K株を保有しおおり、これは党䜓の1.35%に盞圓したす。

Delcath Systems Incの株䞻タむプ䞊䜍3皮は䜕ですか


Delcath Systems Incの株䞻タむプ䞊䜍3皮は、
Rosalind Advisors, Inc.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.

Delcath Systems IncDCTHの株匏を保有しおいる機関の数はいく぀ですか


2025Q4時点で、Delcath Systems Incの株匏を保有しおいる機関は238瀟あり、保有株匏の総垂堎䟡倀は玄18.04Mで、党䜓の62.08%を占めおいたす。2025Q3ず比范しお、機関の持ち株は-2.85%増加しおいたす。

Delcath Systems Incの最倧の収益源は䜕ですか


FY2025Q2においお、HEPZATO KIT郚門がDelcath Systems Incにずっお最倧の収益を生み出しおおり、その金額は22.50Mで、党収益の93.14%を占めおいたす。
KeyAI
î™